Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial

Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial

Abstract Background Large field irradiation had been standard for early-stage follicular lymphoma (FL) for a long time. Although involved field radiotherapy (IF-RT) was recently favored because of the toxicity of large field irradiation, smaller irradiation fields have been accompanied with an incre...

Full description

Bibliographic Details
Main Authors: Laila König, Martin Dreyling, Jan Dürig, Marianne Engelhard, Karin Hohloch, Andreas Viardot, Mathias Witzens-Harig, Meinhard Kieser, Wolfram Klapper, Christiane Pott, Klaus Herfarth
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Trials
Subjects:
Follicular lymphoma
Low-dose radiotherapy
Obinutuzumab
Anti-CD20 antibody
Involved site radiotherapy
PET/CT
Online Access:http://link.springer.com/article/10.1186/s13063-019-3614-y

Internet

http://link.springer.com/article/10.1186/s13063-019-3614-y

Similar Items